SOUTH SAN FRANCISCO (dpa-AFX) - Swiss drug major Roche Holding AG (RHHBY) reported that its IFRS net income for fiscal year 2023 declined about 9% to 12.36 billion Swiss francs from 13.53 billion francs last year. But IFRS net income increased by 7% at constant exchange rates due to the increase in operating profit (IFRS) and lower income tax expenses.
Core earnings per share was 18.57 francs down from 20.30 francs in the prior year.
Annual group sales decreased 7% to 58.72 billion francs from the prior year. But group sales grow by 1% at constant exchange rates, more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidance. Excluding COVID-19 products, Group sales increase by 8%.
Diagnostics Division sales were 13% lower due to high demand for COVID-19 tests in 2022; strong momentum in the Diagnostics Division's base business continues with an increase of 7%.
The company said its board proposed a dividend increase to 9.60 francs.
Looking ahead for fiscal 2024, Roche expects an increase in Group sales in the mid single digit range at constant exchange rates. Core earnings per share are targeted to develop broadly in line with sales growth at constant exchange rates, excluding the impact from resolution of tax disputes in 2023. Roche expects to further increase its dividend in Swiss francs.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2024 AFX News